MaxCyte Non Current Liabilities Other from 2010 to 2024
| MXCT Stock | USD 3.63 0.08 2.25% |
Non Current Liabilities Other | First Reported 2010-12-31 | Previous Quarter 283 K | Current Value 268.9 K | Quarterly Volatility 255.6 K |
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.4 M, Interest Expense of 138.6 K or Selling General Administrative of 31.6 M, as well as many indicators such as Price To Sales Ratio of 11.17, Dividend Yield of 0.0 or PTB Ratio of 2.2. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
MaxCyte | Non Current Liabilities Other |
Latest MaxCyte's Non Current Liabilities Other Growth Pattern
Below is the plot of the Non Current Liabilities Other of MaxCyte over the last few years. It is MaxCyte's Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Other | 10 Years Trend |
|
Non Current Liabilities Other |
| Timeline |
MaxCyte Non Current Liabilities Other Regression Statistics
| Arithmetic Mean | 449,443 | |
| Geometric Mean | 412,268 | |
| Coefficient Of Variation | 56.87 | |
| Mean Deviation | 142,676 | |
| Median | 384,500 | |
| Standard Deviation | 255,577 | |
| Sample Variance | 65.3B | |
| Range | 1.1M | |
| R-Value | 0.26 | |
| Mean Square Error | 65.5B | |
| R-Squared | 0.07 | |
| Significance | 0.35 | |
| Slope | 14,986 | |
| Total Sum of Squares | 914.5B |
MaxCyte Non Current Liabilities Other History
About MaxCyte Financial Statements
MaxCyte shareholders use historical fundamental indicators, such as Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Other | 283 K | 268.9 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.